Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis

@article{Leelakanok2015DomperidoneAR,
  title={Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis},
  author={Nattawut Leelakanok and Andrea Holcombe and Marin L. Schweizer},
  journal={Clinical Drug Investigation},
  year={2015},
  volume={36},
  pages={97-107}
}
Background and ObjectiveDomperidone is a drug used globally for relieving nausea and vomiting and stimulating breast milk production. Several case reports and studies linked domperidone usage with major cardiovascular adverse events (cardiac arrhythmia and sudden cardiac death). However, multiple randomized controlled efficacy studies failed to detect such adverse events. Our objectives were to systematically review and meta-analyze the association between current domperidone exposure and… 
A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide
TLDR
It is indicated that domperidone treatment may not be associated with an overall CV event risk increase at doses ≤30 mg/day and does not result in QT prolongation.
Domperidone for Hypotension in Parkinson's Disease: A Systematic Review.
TLDR
Domperidone may help to ameliorate OH associated with dopaminergic medications in PD, namely when used in conjunction with apomorphine.
Risk of domperidone induced severe ventricular arrhythmia
TLDR
Domperidone, mosapride, or itopride use is associated with an increased risk of severe VA, however, the magnitude of association was modest and dom peridone use does not increase further the risk, compared with other prokinetics.
Cardiovascular Safety of Metoclopramide Compared to Domperidone: A Population-Based Cohort Study
TLDR
The 30-day risk for a hospital encounter with ventricular arrhythmia was low for both metoclopramide and domperidone, with no significant difference in the rate between the two drugs.
Risk of Serious Ventricular Arrhythmia in Users of Gastrointestinal Medications: A Retrospective Cohort Study in China
TLDR
SVA and cardiac arrest are very rare events in patients prescribed medications for gastrointestinal disorders in China and there is no evidence that domperidone carried a higher risk of SVA compared to other gastrointestinal medications.
Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta‐analysis of observational studies
TLDR
Domperidone is associated with an increased risk of sudden cardiac death and ventricular arrhythmia compared to non-use and this association persisted when restricted to higher-quality studies when data were pooled across non-overlapping studies.
Effect of Chronic Domperidone Use on QT Interval
TLDR
The data suggest that domperidone can be safely prescribed at doses of 30 to 80 mg daily for the treatment of gastroparesis and is associated with QTc prolongation in only 6% of patients with no QT interval reaching the point considered to be clinically significant.
Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe
TLDR
Results of the drug-utilization study were inconclusive regarding the effect of the RMM and compliance with the revised labeling for all countries except France, and most physicians in all five countries were aware of the main aspects of the revised labeled.
Gastroparesis: pharmacotherapy and cardiac risk
TLDR
It is important that clinicians managing gastroparesis are aware of the arrhythmogenic potential of drugs used clinically and risk factors that contribute to QT prolongation to safeguard patients at risk for drug-induced cardiac arrhythmia.
Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort
TLDR
The majority of patients remaining on treatment with domperidone experienced an improvement in symptoms of gastroparesis, particularly postprandial fullness, nausea, vomiting, and stomach fullness.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
[Cardiac adverse effects of domperidone in adult patients: a systematic review].
TLDR
Evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults and a significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day.
Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
TLDR
Evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults, and a significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day.
Domperidone and long QT syndrome.
TLDR
Prescribers and other healthcare professionals should take into account the risk of QT syndrome in dom peridone users and avoid administering domperidone in patients concomitantly taking strong CYP3A4 inhibitors or other QT prolonging drugs.
Domperidone and Ventricular Arrhythmia or Sudden Cardiac Death
TLDR
Current use of domperidone, especially high doses, is associated with an increased risk of SCD, and there was a near interaction with health insurance (p = 0.050), all analyses were stratified by insurance.
Cardiovascular Safety Profile and Clinical Experience With High-Dose Domperidone Therapy for Nausea and Vomiting
TLDR
The data indicate that at very high dosing, the prokinetic/antiemetic agent domperidone has a low risk of adverse cardiovascular events while exhibiting good clinical efficacy.
Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.
TLDR
The use of non-cardiac QTc-prolonging drugs in a general population is associated with an increased risk of sudden cardiac death.
Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study
TLDR
Compared with non-use of any study drug, current domperidone use was associated with sudden cardiac death in nested case-control and case-crossover analyses, with a suggestion of higher risk in older persons and users of higher daily doses.
Sudden death in patients receiving drugs tending to prolong the QT interval.
TLDR
Atypical and typical antipsychotic drug use were both strongly associated with raised risks, as were SSRIs, and tricyclic antidepressants were not associated with raise risks.
Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine
TLDR
It is possible that domperidone may be used as a galactogogue without direct risk to healthy breast feeding women, but more safety information should be sought in this situation.
Effect of Domperidone on Insufficient Lactation in Puerperal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
TLDR
Evidence from a few small RCTs of moderate to high quality suggests that domperidone produces a greater increase in breast milk supply than placebo.
...
1
2
3
4
5
...